Anatomical Shoulder Domelock System Study
- Conditions
- Conditions Consequent to Earlier OperationsRevision SurgeryArthritis, DegenerativeArthritis, RheumatoidAvascular NecrosisArthritis;Traumatic
- Interventions
- Device: AS Domelock System
- Registration Number
- NCT03312465
- Lead Sponsor
- Zimmer Biomet
- Brief Summary
The objectives of this study are to confirm safety and performance of the Anatomical Shoulder Domelock System when used in hemi or total shoulder arthroplasty by analysis of standard scoring systems, radiographs and adverse event records.
- Detailed Description
This study is a multicenter, prospective and retrospective, non-controlled PMCF study involving orthopaedic surgeons skilled in hemi and total shoulder arthroplasty procedures. A minimum of six study centers will be involved and a total number of 73 implants will be included into the study.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 73
-
Patient is 18-80 years of age, inclusive
-
Patient is skeletally mature
-
Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history
-
Patient has failed conservative treatment
-
Patient meets at least one of the following indications:
- Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis if bone stock is adequate.
- Avascular necrosis
- Conditions consequent to earlier operations
- Optional use in revision: in some medical conditions (e.g., early revision when adequate bone stock exists), the surgeon may opt to use primary implants in a revision procedure.
Additional criteria for retrospective patients:
- patient has been implanted with the Domelock system before site initiation visit.
- information available must include at minimum demographic information, the operative report and details of the device implanted.
-
Patient is unwilling or unable to give consent or to comply with the follow-up program
-
Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them
-
Patient is known to be pregnant or breastfeeding
-
Patient meets at least one of the contraindications:
- Patient's physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant, e.g., previous surgery, insufficient quality or quantity of bone, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention e.g., absence of musculoligamentous supporting structures, joint neuropathy or other conditions that may lead to inadequate skeletal fixation
- Signs of infection
- Severe instability secondary to advanced loss of osteochondral structure
- Charcot's shoulder (neuroarthropathy)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description AS Domelock System Subjects AS Domelock System Subjects that receive the Anatomical Shoulder Domelock System
- Primary Outcome Measures
Name Time Method Implant Survivorship 10 Years The primary endpoint of this study is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method.
- Secondary Outcome Measures
Name Time Method Clinical Performance 5 Years The secondary endpoint is defined by the performance of the Anatomical Shoulder Domelock System at 5 years, which is assessed by the Constant and Murley score.
The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points.
Trial Locations
- Locations (6)
Univeritätklinik Bagrist
🇨🇭Zürich, Switzerland
Krankenhaus Maria Hilf
🇩🇪Daun, Germany
HELIOS ENDO-Klinik Hamburg
🇩🇪Hamburg, Germany
Universitaire Ziekenhuizen Leuven
🇧🇪Leuven, Belgium
Royal Derby Hospital
🇬🇧Derby, United Kingdom
Universitätsspital Basel
🇨🇭Basel, Switzerland